title: [Anticoagulants and antiplatelet agents in pregnancy].
abstract: Anticoagulants and antiplatelet agents are currently used during pregnancy as treatment or prophylaxis for thromboembolic disease. Main adverse events of these agents are bleeding episodes, which put the pregnancy at risk. Unfractionated and low molecular weight heparins are first-line treatment or prophylaxis for thromboembolism. If an antiplatelet agent is needed, aspirin alone or in combination with heparins can be safely administered. Coumarine derivatives are still contraindicated during pregnancy because of teratogenicity and/or bleeding. No adequate data are yet available on the safety profile of the new antiplatelet agents or the direct thrombin inhibitors. Special considerations are discussed on the risks of regional anesthesia, as well as on nursing during anticoagulation.
authors.affiliation: Hämostase-/Hämatologielabor DZL, Universitätsspital, Basel. dtsakiris@uhbs.ch
authors.forename: D A
authors.initials: DA
authors.lastname: Tsakiris
mesh_terms: D000925:Anticoagulants / Q000008:administration & dosage* / Q000009:adverse effects* / Q000145:classification; D005260:Female; D006470:Hemorrhage / Q000139:chemically induced*; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects* / Q000145:classification; D017410:Practice Guidelines as Topic; D010818:Practice Patterns, Physicians'; D011247:Pregnancy; D011248:Pregnancy Complications / Q000188:drug therapy*; D018570:Risk Assessment / Q000379:methods*; D012307:Risk Factors; D013923:Thromboembolism / Q000188:drug therapy* / Q000517:prevention & control; D016387:Women's Health
chemical_list: D000925:Anticoagulants; D010975:Platelet Aggregation Inhibitors